Narcolepsy vs Cataplexy Explained
A neuroscientist breaks down a common misconception about a rare sleep disorder.
A neuroscientist breaks down a common misconception about a rare sleep disorder.
The granted patent protects the proprietary oral combination therapy through at least 2040, as the company prepares to launch its Phase 2 dose optimization study.
Research presented at ATS 2026 reveals that positional therapy conditions patients to avoid back-sleeping, maintaining obstructive sleep apnea control for up to a year after device withdrawal.
Phase 3 TRIUMPH-1 trial data show retatrutide reduced the AHI by up to 36.1 events per hour alongside substantial weight loss.
Flinders University researchers have led a clinical trial examining how a commonly prescribed ‘sleeping pill’ affects sleep, breathing, and next‑day performance.
Survey findings suggest fatigue remains widespread and debilitating across narcolepsy and idiopathic hypersomnia, even among patients taking medications.
The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.
A new clinical trial from Mass General Brigham found that a drug approved for other indications helped early morning shift workers with shift work disorder stay more alert.
Yanchen Wang is named among 300 scholars in the Regeneron Science Talent Search 2026 for her project investigating the characteristics and risk factors of the parasomnia.